General#

Cell Line

hPSCreg Name
WYUi001-A
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 14th April 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Wuyi University (WYU)

External Databases

BioSamples SAMEA13293330
CLO CLO_0103782

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA13293333

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: 18664681792
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? No
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? No
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? No
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? Yes
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes

Does consent permit research by

an academic institution? No
a public organisation? No
a non-profit company? No
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell type
Valproic Acid-Expanded Umbilical Cord Blood-derived CD34-positive Cells
A preparation of umbilical cord blood (UCB)-derived CD34-positive cells treated with valproic acid (VPA) with potential use in hematopoietic stem cell transplant (HSCT). Upon positive immunomagnetic selection of CD34-positive cells from UCB units, CD34-positive cells are expanded in culture with stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO), and interleukin-3 (IL-3), treated with VPA, and infused into the patient. VPA, a histone deacetylase inhibitor (HDACi), may induce epigenetic changes in UCB hematopoietic stem cells (HSCs), resulting in expansion of CD34-positive cells enriched in short term (ST), intermediate term (IT), and long term (LT) marrow repopulating cells (RCs), which are capable of sustained hematopoietic engraftment following transplantation. Further, VPA-expanded UCB stem cells may shorten the time to neutrophil and platelet recovery and maintain long-term hematopoietic and immune reconstitution compared to untreated UCB grafts.
Synonyms
  • Valproic Acid-Expanded Umbilical Cord Blood-derived CD34-positive Cells
  • VPA-expanded Cord Blood Stem Cells
  • VPA-expanded UCB Stem Cells

Reprogramming method

Vector type Non-integrating
Vector Neon transfection system
Is reprogramming vector detectable?
Unknown

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
SOX2
Yes
Score:
Marker Present Absent
mCpG
OCT4
Self-renewal
Unknown
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Morphology
Ectoderm
Ont Id: UBERON_0000924
Morphology

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX

Other Genotyping (Cell Line)